Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ARX305
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Zhejiang Medicine Co Ltd
Deal Size : $4.0 million
Deal Type : Agreement
Details : ARX305 is the only anti-CD70 ADC in active development that targets CD70, a protein that is overexpressed in a broad range of solid and hematologic tumors, giving it the potential to treat a range of liquid and solid tumor cancers, where CD70 is overexpr...
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
November 09, 2022
Lead Product(s) : ARX305
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Zhejiang Medicine Co Ltd
Deal Size : $4.0 million
Deal Type : Agreement
Reset All
